• By The Financial District


Regeneron Pharmaceuticals Inc. said its coronavirus antibody cocktail - the experimental treatment that US President Donald Trump received - significantly reduced medical visits in a trial of nearly 800 patients with mild-to-moderate COVID-19. 

The firm said patients given the treatment, REGN-COV2, made around 57% fewer COVID-19 related medical visits than those given a placebo over a 29 day period, Michael Erman reported for Reuters. 

The drop was around 72% in patients with one or more risk factors such as being over age 50, obesity, cardiovascular, metabolic, lung, liver or kidney disease, or an immunocompromised status. Last month, the company released early data from the trial showing the treatment reduced viral levels and improved symptoms in non-hospitalized COVID-19 patients. The new data confirm the initial findings, the company said. 

Regeneron's drug is a cocktail of two monoclonal antibodies - manufactured copies of antibodies that are one of the main weapons the immune system generates to fight infections. Trump has credited the Regeneron therapy for his recovery from COVID-19 and said he would push for emergency use authorization (EUA) of that treatment and others like it. He also said he wanted it to be provided at no cost to Americans.

Register for News Alerts

  • LinkedIn
  • Instagram
  • YouTube


The Financial District®  2020